By rray, 31 October, 2023 Contraindication Don t administer to those w hx of severe allergic reaction e g anaphylaxis to any component of the vaccine
By rray, 31 October, 2023 Precaution Delay vaccination for those experiencing moderate or severe acute illness w or w o fever
By rray, 31 October, 2023 Coadministration Simultaneous administration of nirsevimab w age appropriate vaccines is recommended nbsp In clinical trials when nirsevimab was administered concomitantly w routine childhood vaccines the safety and reactogenicity profile was similar to w
By rray, 31 October, 2023 Timing Nirsevimab may be given in most of the continental U S from Oct Mar Because timing of the onset peak and decline of RSV activity may vary administration schedules may be adjusted based on local RSV activity nbsp Tropical climates including southern
By rray, 31 October, 2023 Second dose Only children who meet high risk criteria should receive 1 dose of nirsevimab 1 dose in their 1st RSV season and 1 dose in their 2nd RSV season Healthy newborns born at the end of RSV season who received nirsevimab around the time of delivery
By rray, 31 October, 2023 Nirsevimab may be given to age eligible infants and children who haven t received a dose at any time during the RSV season
By rray, 31 October, 2023 Infants and children 8 19 mo at increased risk of severe RSV dz Give nirsevimab shortly before the start of the RSV season
By rray, 31 October, 2023 Infants born shortly before and during the RSV season Aim for nirsevimab administration in the 1st wk of life May occur during the birth hospitalization or in the out pt setting Infants w prolonged birth hospitalizations because of prematurity or other ca